These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10688991)

  • 1. (R)-ACX is a novel sufonylurea compound with potent, quick and short-lasting hypoglycemic activity.
    Seri K; Sanai K; Kurashima K; Imamura Y; Akita H
    Eur J Pharmacol; 2000 Feb; 389(2-3):253-6. PubMed ID: 10688991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemic effect of S(-)-hydroxyhexamide, a major metabolite of acetohexamide, and its enantiomer R(+)-hydroxyhexamide.
    Imamura Y; Sanai K; Seri K; Akita H
    Life Sci; 2001 Sep; 69(16):1947-55. PubMed ID: 11693275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (R)-ACX, a pancreatic beta-cell selective sulfonylurea, does not aggravate myocardial ischemia-reperfusion damage.
    Namekata I; Yamaguchi Y; Moriguchi S; Yamazaki S; Terasawa A; Yamagishi R; Aikawa T; Saito T; Kurashima K; Seri K; Imamura Y; Akita H; Shigenobu K; Tanaka H
    Eur J Pharmacol; 2007 Dec; 577(1-3):211-8. PubMed ID: 17927975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extract isolated from Angelica hirsutiflora with insulin secretagogue activity.
    Leu YL; Chen YW; Yang CY; Huang CF; Lin GH; Tsai KS; Yang RS; Liu SH
    J Ethnopharmacol; 2009 Jun; 123(2):208-12. PubMed ID: 19429364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.
    Ohnota H; Koizumi T; Tsutsumi N; Kobayashi M; Inoue S; Sato F
    J Pharmacol Exp Ther; 1994 May; 269(2):489-95. PubMed ID: 8182516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic aspects of two sulphonylurea derivatives glipizide and glibenclamide.
    Artini D; Abbiati R; Orsini G; Parenti MA; Bloch K; Daturi S; Mandelli V
    Diabetologia; 1973 Sep; ():311-6. PubMed ID: 4204091
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen.
    Sugawara K; Honda K; Reien Y; Yokoi N; Seki C; Takahashi H; Minami K; Mori I; Matsumoto A; Nakaya H; Seino S
    PLoS One; 2016; 11(10):e0164785. PubMed ID: 27764176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166).
    Ikenoue T; Akiyoshi M; Fujitani S; Okazaki K; Kondo N; Maki T
    Br J Pharmacol; 1997 Jan; 120(1):137-45. PubMed ID: 9117089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glimepiride and glibenclamide on insulin and glucagon secretion by the perfused rat pancreas.
    Ledercq-Meyer V; Akkan AG; Marchand J; Malaisse WJ
    Biochem Pharmacol; 1991 Sep; 42(8):1634-7. PubMed ID: 1930290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.
    Ladrière L; Malaisse-Lagae F; Fuhlendorff J; Malaisse WJ
    Eur J Pharmacol; 1997 Sep; 335(2-3):227-34. PubMed ID: 9369378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
    Remedi MS; Nichols CG
    PLoS Med; 2008 Oct; 5(10):e206. PubMed ID: 18959471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats.
    Takasaki K; Nakajima T; Ueno K; Nomoto Y; Higo K
    J Pharmacol Sci; 2004 Jun; 95(2):291-3. PubMed ID: 15215655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin release from a cloned hamster B-cell line (HIT-T15). The effects of glucose, amino acids, sulphonylureas and colchicine.
    Lambert DG; Hughes K; Atkins TW
    Biochem Biophys Res Commun; 1986 Oct; 140(2):616-25. PubMed ID: 3535793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
    Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
    Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis.
    Lehtihet M; Welsh N; Berggren PO; Cook GA; Sjoholm A
    Am J Physiol Endocrinol Metab; 2003 Aug; 285(2):E438-46. PubMed ID: 12684219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Extrapancreatic effects of sulfonylurea compounds. IV. Increase of the effect of insulin due to tolbutamide, glibornuride, and glibenclamide in vitro].
    Beyer J; Gather W; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2179. PubMed ID: 4198966
    [No Abstract]   [Full Text] [Related]  

  • 19. Sulfonylurea binding to a low-affinity site inhibits the Na/K-ATPase and the KATP channel in insulin-secreting cells.
    Ribalet B; Mirell CJ; Johnson DG; Levin SR
    J Gen Physiol; 1996 Feb; 107(2):231-41. PubMed ID: 8833343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice.
    Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y
    Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.